KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Construction in Progress (2016 - 2017)

Historic Construction in Progress for Regeneron Pharmaceuticals (REGN) over the last 5 years, with Q4 2017 value amounting to $408.9 million.

  • Regeneron Pharmaceuticals' Construction in Progress rose 2819.69% to $408.9 million in Q4 2017 from the same period last year, while for Dec 2017 it was $408.9 million, marking a year-over-year increase of 2819.69%. This contributed to the annual value of $408.9 million for FY2017, which is 2819.69% up from last year.
  • As of Q4 2017, Regeneron Pharmaceuticals' Construction in Progress stood at $408.9 million, which was up 2819.69% from $318.9 million recorded in Q4 2016.
  • Regeneron Pharmaceuticals' Construction in Progress' 5-year high stood at $579.8 million during Q4 2015, with a 5-year trough of $142.4 million in Q4 2013.
  • For the 5-year period, Regeneron Pharmaceuticals' Construction in Progress averaged around $384.4 million, with its median value being $408.9 million (2017).
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Construction in Progress skyrocketed by 23169.28% in 2014 and then plummeted by 4499.65% in 2016.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Construction in Progress stood at $142.4 million in 2013, then soared by 231.69% to $472.2 million in 2014, then rose by 22.79% to $579.8 million in 2015, then crashed by 45.0% to $318.9 million in 2016, then grew by 28.2% to $408.9 million in 2017.
  • Its last three reported values are $408.9 million in Q4 2017, $318.9 million for Q4 2016, and $579.8 million during Q4 2015.